This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pederson, L. C. Articles by Stackhouse, M. A. Search for Related Content PubMed PubMed Citation Articles by Pederson, L. C. Articles by Stackhouse, M. A.

Molecular Chemotherapy Combined with Radiation Therapy Enhances Killing of Cholangiocarcinoma Cells in Vitro and in Vivo

Departments of Surgery [L. C. P., S. M. V.], Radiation Oncology [D. J. B., S. R. K., M. A. S.], Biostatistics Unit [M. S. M.], and Gene Therapy Program [D. T. C.], University of Alabama at Birmingham, Birmingham, Alabama 35294

Cholangiocarcinoma is a virtually incurable tumor, resistant to current surgical, chemotherapy, and radiotherapy interventions. We applied the gene therapy strategy of toxin gene conversion of nontoxic prodrug to chemotherapeutic drug in combination with radiation therapy to the treatment of cholangiocarcinoma. In this regard, 5-fluorouracil (5-FU) is an accepted radiosensitizing and chemotherapeutic agent presently used in cancer therapy. The Escherichia coli enzyme cytosine deaminase (CD) converts the prodrug 5-fluorocytosine (5-FC) to 5-FU. Therefore, our goal was to express the CD gene in the human cholangiocarcinoma cell line, SK-ChA-1, assess the cytotoxicity of intracellular production of 5-FU, and determine any enhanced cell killing by the addition of external beam radiation.

The susceptibility of SK-ChA-1 cells to recombinant adenoviral infection was determined by fluorescence-activated cell sorting analysis. We used the recombinant adenoviral vector AdCMVLacZ, encoding the E. coli ß-galactosidase reporter gene under control of the human cytomegalovirus (CMV) promoter, to infect SK-ChA-1 and HeLa cells at 10 and 100 plaque forming units (pfu)/cell, followed by FACS analysis. To evaluate CD-mediated conversion of 5-FC to 5-FU and subsequent cytotoxicity, SK-ChA-1 cells were infected with the recombinant adenovirus AdC-MVCD, which encodes CD. Cells were then plated in 96-well microtiter plates and exposed to varying concentrations of 5-FC. Cell proliferation assays (tetrazolium salt conversion to formazan colorimetric assay) were performed beginning 2–8 days after plating. We evaluated the effects of external beam radiation using a single 8 Gy ⁶⁰Co dose to AdCMVCD infected cells, with prior exposure to 5-FC for 2–3 days. MTS assays were performed following radiation treatment. Radiation dose-response analysis, via clonogenic assay, was used as a more sensitive assay to confirm the interaction of the treatment conditions. s.c. SK-ChA-1 tumors in athymic nude mice were established, which then received three intratumoral injections of 1 x 10⁹ pfu AdCMVCD. Mice received i.p. injections of 400 mg/kg of 5-FC twice daily for 7 days beginning the day of initial AdCMVCD injection (day -2). The radiation treatment group received 10 Gy of ⁶⁰Co exposure to their tumor on day 0.

SK-ChA-1 cells were efficiently transduced (48.7 and 99.2%) by 10 and 100 pfu/cell of AdCMVLacZ, respectively. From 37.9 to 84.4% of SK-ChA-1 cells were killed following infection with 10 pfu/cell AdCMVCD and 8 days of exposure to various concentrations of 5-FC (5, 10, 30, 50, and 100 µg/ml). Higher 5-FC concentrations and longer duration of exposure resulted in greater cell killing. Radiation treatment (8 Gy) enhanced cell killing by greater than 70% when combined with 10 or 20 µg/ml of 5-FC. Radiation dose-response analysis with clonogenic assay confirmed enhanced SK-ChA-1 cell cytotoxicity as a result of radiation treatment following AdCMVCD infection and 5-FC exposure, with radiobiological parameters = 0.44 and D₀ = 0.96. Combined treatment of SK-ChA-1 tumors with AdCMVCD, 5-FC, and radiation in animals resulted in significantly greater survival, time to tumor regrowth, and doubling time compared to the nonradiation treatment group (P = 0.03, 0.015, and 0.002, respectively). Significantly greater change in tumor size, smaller ratio of final tumor size to original tumor size, and smaller final tumor size were observed in the radiation treatment group compared to the no radiation treatment group (P = 0.02, 0.03, and 0.03, respectively).

Human cholangiocarcinoma cells were transduced with a recombinant adenovirus in vitro at high efficiency and were susceptible to CD-mediated intracellular 5-FU production. Radiobiological survival curve parameters confirmed an interactive cytotoxic effect when viral infection and prodrug therapy were combined with external beam radiation exposure. Preliminary in vivo studies demonstrated effective tumor growth inhibition following AdCMVCD injection, 5-FC administration, and radiation treatment. These findings suggest the potential for integrating molecular chemotherapy strategies with radiation therapy for the treatment of cholangiocarcinoma.

¹ To whom requests for reprints should be addressed, at Lurleen B. Wallace Cancer Center, 1824 6th Avenue South, Department of Radiation Oncology, WTI 674, University of Alabama at Birmingham, Birmingham, AL 35294. Phone: (205) 934-7077; Fax: (205) 975-7060; E-mail: Lagan@uab.edu.

Received 4/25/97. Accepted 8/ 1/97.

This article has been cited by other articles:

				S. J. Advani, R. R. Weichselbaum, and S. J. Chmura Enhancing Radiotherapy With Genetically Engineered Viruses J. Clin. Oncol., September 10, 2007; 25(26): 4090 - 4095. [Abstract] [Full Text] [PDF]

				N. N. Khodarev, M. Beckett, E. Labay, T. Darga, B. Roizman, and R. R. Weichselbaum STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells PNAS, February 10, 2004; 101(6): 1714 - 1719. [Abstract] [Full Text] [PDF]

				M. Ramnaraine, W. Pan, M. Goblirsch, C. Lynch, V. Lewis, P. Orchard, P. Mantyh, and D. R. Clohisy Direct and Bystander Killing of Sarcomas by Novel Cytosine Deaminase Fusion Gene Cancer Res., October 15, 2003; 63(20): 6847 - 6854. [Abstract] [Full Text] [PDF]

				M. Zhang, S. Li, M. K. Nyati, S. DeRemer, J. Parsels, A. Rehemtulla, W. D. Ensminger, and T. S. Lawrence Regional Delivery and Selective Expression of a High-Activity Yeast Cytosine Deaminase in an Intrahepatic Colon Cancer Model Cancer Res., February 1, 2003; 63(3): 658 - 663. [Abstract] [Full Text] [PDF]

				C. R. Miller, C. R. Williams, D. J. Buchsbaum, and G. Y. Gillespie Intratumoral 5-Fluorouracil Produced by Cytosine Deaminase/5-Fluorocytosine Gene Therapy Is Effective for Experimental Human Glioblastomas Cancer Res., February 1, 2002; 62(3): 773 - 780. [Abstract] [Full Text] [PDF]

				K. M. Anderson and J. E. Harris Selected Features of Nonendocrine Pancreatic Cancer Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537. [Abstract] [Full Text] [PDF]

				E. Kievit, M. K. Nyati, E. Ng, L. D. Stegman, J. Parsels, B. D. Ross, A. Rehemtulla, and T. S. Lawrence Yeast Cytosine Deaminase Improves Radiosensitization and Bystander Effect by 5-Fluorocytosine of Human Colorectal Cancer Xenografts Cancer Res., December 1, 2000; 60(23): 6649 - 6655. [Abstract] [Full Text]

				S. Couillard, M. Gutman, F. Labrie, B. Candas, and C. Labrie Effect of Combined Treatment with the Pure Antiestrogen EM-800 and Radiotherapy on the Growth of Human ZR-75-1 Breast Cancer Xenografts in Nude Mice Cancer Res., October 1, 1999; 59(19): 4857 - 4863. [Abstract] [Full Text] [PDF]

				M. Gutman, S. Couillard, F. Labrie, B. Candas, and C. Labrie Effects of the Antiestrogen EM-800 (SCH 57050) and Cyclophosphamide Alone and in Combination on Growth of Human ZR-75-1 Breast Cancer Xenografts in Nude Mice Cancer Res., October 1, 1999; 59(20): 5176 - 5180. [Abstract] [Full Text] [PDF]

				E. Kievit, E. Bershad, E. Ng, P. Sethna, I. Dev, T. S. Lawrence, and A. Rehemtulla Superiority of Yeast over Bacterial Cytosine Deaminase for Enzyme/Prodrug Gene Therapy in Colon Cancer Xenografts Cancer Res., April 1, 1999; 59(7): 1417 - 1421. [Abstract] [Full Text] [PDF]